How to Cite
Abstract
Proton pump inhibitors (PPIs) are the most effective current treatment against diseases related to gastric hyperacidity. The prescription of this drugs has been increasing exponentially worldwide. In the United States, it represents the third most used group of drugs, and since its introduction in 1989, its use in adults increased from 2.1% to 4.2% in 2012. It has been of great interest in the scientific community and the pharmacological company to investigate and hypothesize about the possible adverse effects that arise from the excessive and long-term use of this group of drugs. Some are supported by literature, yet others are just "false alarms".
Keywords
References
Katzung, BG. Basic and clinical pharmacology, 9th edition. New York: Lange Medical Books; 2004.
Spechler, Stuart Jon. Proton Pump Inhibitors What the Internist Needs to Know Med Clin N Am 103 (2019) 1–14.
Vaezi MF, Yang YX, Howden CW. Complications of proton pump inhibitor therapy. Gastroenterology 2017; 153:35–48.
Blank ML, Parkin L, Paul C, Herbison P. A nation- wide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use. Kidney Int. 2014;86(4):837–44.
A. Corsonello, F. Lattanzio. Cardiovascular and non cardiovascular concerns in proton pump inhibitor use. Are they safe?. Trends in Cardiovascular Medicine 29 (2019) 353–360.
Martí-Cabrera, Miguel; Martí-Masanet, Miguel; Esplugues Juan. ¿Es real el riesgo de osteoporosis y riesgo de fracturas con el uso crónico de inhibidores de la bomba de protones?. Gastroenterol Hepatol. 2011;34(4):271—277.
B. Haenisch, K. von Holt, B. Wiese et al., “Risk of dementia in elderly patients with the use of proton pump inhibitors,” .European Archives of Psychiatry and Clinical Neuroscience, vol. 265, no. 5, pp. 419–428, 2015.
S.-Y. Tai, C.-Y. Chien, D.-C. Wu et al., Risk of dementia from proton pump inhibitor use in Asian population: a nationwide cohort study in Taiwan. PLoS One, vol. 12, no. 2, article e0171006, 2017.
Freedberg, Daniel; Kim, Lawrence; Yang, Yu-Xiao.The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association Gastroenterology. 2017;152:706–715
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am SocNephrol 2016; 27(10):3153–3163.
Corsonello, Andrea; Lattanzio, Fabrizia. Cardiovascular and non cardiovascular concerns with proton pump inhibitors: Are they safe?. Trends in Cardiovascular Medicine 29 (2019) 353–360.
Brisebois et al. Risks of Proton Pump Inhibitors .Laryngoscope Investigative Otolaryngology 3: December 2018.
Hauben M, Horn S, Reich L, Younus M. Association between gastric acid suppressants and Clostridium difficilecolitis and community-acquired pneumonia: analysis using pharmacovigilance tools. Int J Infect Dis 2007; 11: 417-422.
Yamamoto Kenta et al. Influence of proton pump inhibitors on microbiota in chronic liver disease patients. Hepatology International (2019) 13:234–244.
Kieboom BCT, Kiefte-de Jong JC, Eijgelsheim M, et al. Proton Pump Inhibitors and Hypomagnesemia in the General Population: A Population-Based Cohort Study. Am J Kidney Dis. 2015; 66(5):775–782.
Hung, Tsung Hsing et al. Effect of proton pump inhibitors in hospitalization on mortality of patients with hepatic encephalopathy and cirrhosis but no active gastrointestinal bleeding. Clinics and Research in Hepatology and Gastroenterology (2018) 42, 353—359.
Thomson Alan et al. Safety of the long term use of protin pump inhibitors. World J Gastroenterol 2010 May 21; 16(19): 2323-2330.
Brusselaers N, Wahlin K, Engstrand L, Lagergren J: Maintenance therapy with pro- ton pump inhibitors and risk of gastric cancer: a nationwide population-based cohort study in Sweden. BMJ Open 2017;7: e017739.
Courley A. Douglas. Safety and Complications of Long-Term Proton Pump Inhibitor Therapy: Getting Closer to the Truth. 2019. AGA. Editorials.
Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. Gastroenterology 2019;157:682–691.
Attwood SE, Ell C, Galmiche JP, et al. Long-term safety of proton pump inhibitor therapy assessed under controlled, randomised clinical trial conditions: data from the SOPRAN and LOTUS studies. Aliment Pharmacol Ther 2015;41:1162–1174.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2021 Array